BRAVE-HCM: The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction (clinicaltrials.gov) - Sep 16, 2026 - P4 | N=132 | Enrolling by invitation | Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine | Not yet recruiting ➔ Enrolling by invitation | Trial primary completion date: Jul 2026 ➔ Nov 2026
Enrollment open • Real-world evidence • Trial primary completion date • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy
|